Skip to content
Clinical Trials – home

Emmaues

Verified siteinfo

Belgium Liersesteenweg 435, 2800 Mechelen, Belgium

  • 32 trials recruiting
  • Non-small cell lung cancer · Arteriosclerosis · Asthma
  • Adults and children

About Specializations

Emmaues in Mechelen, Belgium specialises in clinical trials of conditions such as Non-small cell lung cancer, Arteriosclerosis, Asthma, Chronic obstructive pulmonary disease, and other specialisations. This site conducts important research.

Main research areas of the site

Oncology and Hematologic Malignancies

At Emmaues, cancer research is a major focus, with studies spanning non-small cell lung cancer, small cell lung cancer, breast cancer, colorectal cancer, and several lymphomas and leukemias. The trials are designed to test new treatment options, compare them with current standards, and improve outcomes for patients with advanced or hard-to-treat disease.

  • Non-small cell lung cancer, small cell lung cancer, and lung cancer are central research areas
  • Breast cancer, colorectal cancer, and neuroendocrine tumours are also represented
  • Studies in CLL, SLL, DLBCL, and multiple myeloma explore better treatment effectiveness

Much of the work at this hospital-based research site is aimed at evaluating targeted therapies, immunotherapy combinations, and more effective approaches for patients whose cancers have progressed after earlier treatment.

Respiratory Medicine and Pulmonary Disease

Research in respiratory tract diseases is especially active, covering asthma, COPD, chronic cough, bronchiectasis, and pneumonia. These trials focus on improving symptom control, reducing flare-ups, and finding better long-term options for people living with chronic breathing disorders.

  • Asthma studies include uncontrolled and type 2 inflammatory disease
  • COPD trials aim to lower exacerbations and support better daily function
  • Chronic cough, bronchiectasis, and pneumonia research addresses persistent respiratory symptoms and infection-related illness

The respiratory portfolio at Emmaues also includes work on immune-based therapies, reflecting a broader effort to improve both treatment effectiveness and quality of life.

Cardiovascular, Metabolic, and Kidney-Related Research

Trials in cardiovascular diseases and nutritional and metabolic diseases examine conditions such as atherosclerotic cardiovascular disease, elevated lipoprotein(a), hypertriglyceridemia, obesity, and weight management. There is also research involving chronic kidney disease and systemic inflammation, with the goal of reducing major heart events and improving metabolic health.

  • Cardiovascular disease studies focus on preventing heart attack, stroke, and related complications
  • Lipoprotein(a) and triglyceride research explores new ways to lower lipid-related risk
  • Obesity and weight management trials assess treatments that support healthier body weight

These studies at the AZ Sint Maarten department in Mechelen aim to improve prevention and long-term control of cardiometabolic disease.

Immunology, Infectious Disease, and Vaccination Research

This site also contributes to research on virus diseases, bacterial infections, and immune system phenomena. Trials include studies of influenza, respiratory syncytial virus, human metapneumovirus, urinary tract infections, and COVID-19, along with vaccine studies in healthy adults and older populations.

  • Influenza and RSV vaccine studies evaluate protection and immune response
  • UTI research looks at prevention of E. coli-related infection
  • COVID-19 and other respiratory infection studies assess treatment support and disease control

The research activity here reflects a strong interest in preventing infection, strengthening immune protection, and improving care for common community and seasonal illnesses.

Neurology and Symptom Management

Clinical trials in nervous system diseases at Emmaues include migraine and chronic cough-related symptom burden, with a broader emphasis on easing persistent symptoms that affect daily life. These studies aim to improve control of recurring neurological and airway-related complaints.

  • Chronic migraine and episodic migraine are being studied to reduce attack frequency
  • Refractory and unexplained chronic cough research targets troublesome long-term symptoms
  • Trials focus on better symptom relief and improved patient well-being

By addressing conditions that can be disabling even when not life-threatening, this research supports more practical and patient-centered care.

Digestive, Liver, and Inflammation-Related Research

The site’s work in digestive system diseases includes studies of cirrhosis and other conditions linked to liver damage and fluid balance. Some trials also examine inflammation-related disease processes, reflecting interest in how chronic illness affects multiple organ systems.

  • Cirrhosis of the liver is a key area of investigation
  • Studies evaluate treatments intended to improve disease control and patient stability
  • Immune system and inflammation research connects with broader internal medicine care

These studies add to the broader clinical research profile at the hospital/clinic, where complex chronic diseases are being studied across several specialties.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Liersesteenweg 4352800 MechelenBelgium
Recruiting now
32 trials
Conditions studied
52
Partner status
Verified site

More sites in MechelenBelgium

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

81 clinical trials

Study of sotorasib, panitumumab and a drug combination for patients with metastatic colorectal cancer with KRAS p.G12C mutation.

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Bevacizumab
  • Sponsor:Amgen Inc.

Asthma

Recruiting

Study to evaluate the long-term safety and effectiveness of lunsekimig in adults with moderate to severe asthma

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study on the Long-term Safety and Efficacy of Pembrolizumab and Lenvatinib for Patients with Advanced Tumors

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Favezelimab
  • Sponsor:Merck Sharp & Dohme LLC

Study of LY3537982, pembrolizumab, and a drug combination for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Eli Lilly & Co.

Influenza+1

Recruiting

Efficacy and safety of the investigational mRNA influenza vaccine gskvx000000077430 (drug combination) in adults ≥ 65 years

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:65+ years · Healthy volunteers
  • Substances:INFLUENZA A VIRUS, A/CROATIA/10136RV/2023 (H3N2) LIKE STRAIN X-425A, INACTIVATED
  • Sponsor:GlaxoSmithKline Biologicals

Obesity+1

Recruiting

Phase 3 Extension Trial Evaluating Long‑Term Efficacy, Safety and Tolerability of maridebart cafraglutide in Adults with Obesity

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Phase 3 Study of Subcutaneous vs Intravenous Tarlatamab with Siltuximab in Relapsed Extensive-Stage Small Cell Lung Cancer after Platinum Chemotherapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Siltuximab
  • Sponsor:Amgen Inc.

Graves' disease

Recruiting

Phase 3 Randomized Placebo‑Controlled Study of Efgartigimod Alfa in Adults with Graves’ Disease Inadequately Controlled by Antithyroid Drugs

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Asthma

Recruiting

Efficacy and Safety of Depemokimab for Early Intervention in Adults and Adolescents with Type 2 Asthma at Risk of Exacerbations

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Depemokimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Efficacy and safety of lunsekimig in adults with inadequately controlled eosinophilic COPD: a randomized, double‑blind, placebo‑controlled trial

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Lunsekimig
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Asthma

Recruiting

Efficacy and safety of GB-0895 as adjunctive therapy in adults and adolescents with severe uncontrolled asthma (randomized, placebo‑controlled)

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Generate Biomedicines Inc.

VMX-C001 in Patients Taking Factor Xa Inhibitors Who Need Urgent Surgery or an Invasive Procedure With High Bleeding Risk

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:VMX-C001
  • Sponsor:VarmX B.V.
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.